S L Huskinson1, D M Platt2, M Brasfield2, M E Follett2, T E Prisinzano3, B E Blough4, K B Freeman2. 1. Division of Neurobiology and Behavior Research, Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216, USA. shuskinson@umc.edu. 2. Division of Neurobiology and Behavior Research, Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, 39216, USA. 3. Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY, 40536, USA. 4. Research Triangle Institute, Research Triangle Park, NC, 27709, USA.
Abstract
RATIONALE: Kappa-opioid receptor (KOR) agonists are antinociceptive but have side effects that limit their therapeutic utility. New KOR agonists have been developed that are fully efficacious at the KOR but may produce fewer or reduced side effects that are typical of KOR agonists. OBJECTIVES: We determined behavioral profiles for typical and atypical KOR agonists purported to differ in intracellular-signaling profiles as well as a mu-opioid receptor (MOR) agonist, oxycodone, using a behavioral scoring system based on Novak et al. (Am J Primatol 28:124-138, 1992, Am J Primatol 46:213-227, 1998) and modified to quantify drug-induced effects (e.g., Duke et al. J Pharmacol Exp Ther 366:145-157, 2018). METHODS: Six adult male rhesus monkeys were administered a range of doses of the typical KOR agonists, U50-488H (0.0032-0.1 mg/kg) and salvinorin A (0.00032-0.01 mg/kg); the atypical KOR agonists, nalfurafine (0.0001-0.001 mg/kg) and triazole 1.1 (0.01-0.32 mg/kg); the MOR agonist, oxycodone (0.0032-0.32 mg/kg); and as controls, cocaine (0.032-0.32 mg/kg) and ketamine (0.32-10 mg/kg). For time-course determinations, the largest dose of each KOR agonist or MOR agonist was administered across timepoints (10-320 min). In mixture conditions, oxycodone (0.1 mg/kg) was followed by KOR-agonist administration. RESULTS: Typical KOR agonists produced sedative-like and motor-impairing effects. Nalfurafine was similar to typical KOR agonists on most outcomes, and triazole 1.1 produced no effects on its own except for reducing scratch during time-course determinations. In the mixture, all KOR agonists reduced oxycodone-induced scratching, U50-488H and nalfurafine reduced species-typical activity, and U50-488H increased rest/sleep posture. CONCLUSIONS: Atypical "biased" KOR agonists produce side-effect profiles that are relatively benign (triazole 1.1) or reduced (nalfurafine) compared to typical KOR agonists.
RATIONALE: Kappa-opioid receptor (KOR) agonists are antinociceptive but have side effects that limit their therapeutic utility. New KOR agonists have been developed that are fully efficacious at the KOR but may produce fewer or reduced side effects that are typical of KOR agonists. OBJECTIVES: We determined behavioral profiles for typical and atypical KOR agonists purported to differ in intracellular-signaling profiles as well as a mu-opioid receptor (MOR) agonist, oxycodone, using a behavioral scoring system based on Novak et al. (Am J Primatol 28:124-138, 1992, Am J Primatol 46:213-227, 1998) and modified to quantify drug-induced effects (e.g., Duke et al. J Pharmacol Exp Ther 366:145-157, 2018). METHODS: Six adult male rhesus monkeys were administered a range of doses of the typical KOR agonists, U50-488H (0.0032-0.1 mg/kg) and salvinorin A (0.00032-0.01 mg/kg); the atypical KOR agonists, nalfurafine (0.0001-0.001 mg/kg) and triazole 1.1 (0.01-0.32 mg/kg); the MOR agonist, oxycodone (0.0032-0.32 mg/kg); and as controls, cocaine (0.032-0.32 mg/kg) and ketamine (0.32-10 mg/kg). For time-course determinations, the largest dose of each KOR agonist or MOR agonist was administered across timepoints (10-320 min). In mixture conditions, oxycodone (0.1 mg/kg) was followed by KOR-agonist administration. RESULTS: Typical KOR agonists produced sedative-like and motor-impairing effects. Nalfurafine was similar to typical KOR agonists on most outcomes, and triazole 1.1 produced no effects on its own except for reducing scratch during time-course determinations. In the mixture, all KOR agonists reduced oxycodone-induced scratching, U50-488H and nalfurafine reduced species-typical activity, and U50-488H increased rest/sleep posture. CONCLUSIONS: Atypical "biased" KOR agonists produce side-effect profiles that are relatively benign (triazole 1.1) or reduced (nalfurafine) compared to typical KOR agonists.
Authors: Donna M Platt; James K Rowlett; Roger D Spealman; James Cook; Chunrong Ma Journal: Psychopharmacology (Berl) Date: 2002-09-04 Impact factor: 4.530
Authors: Eduardo R Butelman; Marek Mandau; Kevin Tidgewell; Thomas E Prisinzano; Vadim Yuferov; Mary Jeanne Kreek Journal: J Pharmacol Exp Ther Date: 2006-10-23 Impact factor: 4.030
Authors: Vanessa Minervini; Hannah Y Lu; Jahnavi Padarti; Daniela C Osteicoechea; Charles P France Journal: Psychopharmacology (Berl) Date: 2018-05-22 Impact factor: 4.530
Authors: Matthew L Lazenka; Megan J Moerke; E Andrew Townsend; Kevin B Freeman; F Ivy Carroll; S Stevens Negus Journal: Psychopharmacology (Berl) Date: 2017-10-24 Impact factor: 4.530
Authors: Daniela Rüedi-Bettschen; James K Rowlett; Sundari Rallapalli; Terry Clayton; James M Cook; Donna M Platt Journal: Alcohol Clin Exp Res Date: 2012-11-05 Impact factor: 3.455
Authors: C Austin Zamarripa; Tanya Pareek; Hayley M Schrock; Thomas E Prisinzano; Bruce E Blough; Kenneth J Sufka; Kevin B Freeman Journal: Psychopharmacology (Berl) Date: 2021-08-25 Impact factor: 4.530
Authors: Lais F Berro; C Austin Zamarripa; Joseph T Talley; Kevin B Freeman; James K Rowlett Journal: Addict Behav Date: 2022-07-22 Impact factor: 4.591
Authors: Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell Journal: J Pharmacol Exp Ther Date: 2020-09-10 Impact factor: 4.030
Authors: Angela N Duke; V V N Phani Babu Tiruveedhula; Dishary Sharmin; Daniel E Knutson; James M Cook; Donna M Platt; James K Rowlett Journal: Drug Alcohol Depend Date: 2021-08-27 Impact factor: 4.492